In newly released Draft Guidance from the U.S. Food and Drug Administration (FDA) entitled, Platform Technology Designation Program for Drug Development, the FDA addresses its new designation program for platform technologies, which is intended to bring efficiencies to drug development, manufacturing, and review processes for applications that incorporate designated platform technologies.
Read the full alert here.
The post Designating a Platform Technology: FDA’s Long-Awaited Draft Guidance appeared first on Life Sciences Perspectives.